Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HIV-1 Infection
Conditions
HIV-1 Infection
Trial Timeline
Feb 22, 2013 → Dec 31, 2018
NCT ID
NCT01641367About Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available
Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available is a approved stage product being developed by AbbVie for HIV-1 Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01641367. Target conditions include HIV-1 Infection.
What happened to similar drugs?
20 of 20 similar drugs in HIV-1 Infection were approved
Approved (20) Terminated (2) Active (0)
✅efavirenz + emtricitabina + tenofovir + rilpivirina + emtricitabina + tenofovirGilead SciencesApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01641367 | Approved | Completed |
Competing Products
20 competing products in HIV-1 Infection